|
🐜
|
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
44 auth.
F. V. D. van den Hoogen,
D. Khanna,
J. Fransen,
S. Johnson,
M. Baron,
A. Tyndall,
M. Matucci-Cerinic,
R. Naden,
T. Medsger,
P. Carreira,
G. Riemekasten,
P. Clements,
C. Denton,
O. Distler,
Y. Allanore,
...
D. Furst,
A. Gabrielli,
M. Mayes,
J. V. van Laar,
J. Seibold,
L. Czirják,
V. Steen,
M. Inanç,
O. Kowal-Bielecka,
U. Müller-Ladner,
G. Valentini,
D. Veale,
M. Vonk,
U. Walker,
L. Chung,
D. Collier,
Mary Ellen Csuka,
B. Fessler,
S. Guiducci,
A. Herrick,
V. Hsu,
S. Jimenez,
B. Kahaleh,
P. Merkel,
S. Sierakowski,
R. Silver,
R. Simms,
J. Varga,
J. Pope
|
11 |
2013 |
11
🐜
|
|
🐜
|
Update of EULAR recommendations for the treatment of systemic sclerosis
37 auth.
O. Kowal-Bielecka,
J. Fransen,
J. Avouac,
M. Becker,
A. Kułak,
Y. Allanore,
O. Distler,
P. Clements,
M. Cutolo,
L. Czirják,
N. Damjanov,
F. del Galdo,
C. Denton,
J. Distler,
I. Foeldvari,
...
Kim Figelstone,
M. Frerix,
D. Furst,
S. Guiducci,
N. Hunzelmann,
D. Khanna,
M. Matucci-Cerinic,
A. Herrick,
F. V. D. van den Hoogen,
J. V. van Laar,
G. Riemekasten,
R. Silver,
V. Smith,
A. Sulli,
I. Tarner,
A. Tyndall,
Joep Welling,
F. Wigley,
G. Valentini,
U. Walker,
F. Zulian,
U. Müller-Ladner
|
9 |
2015 |
9
🐜
|
|
🦁
|
Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.
45 auth.
J. V. van Laar,
D. Farge,
J. Sont,
K. Naraghi,
Z. Marjanovic,
J. Larghero,
A. Schuerwegh,
E. Marijt,
M. Vonk,
A. Schattenberg,
M. Matucci-Cerinic,
A. Voskuyl,
A. A. van de Loosdrecht,
T. Daikeler,
I. Kötter,
...
M. Schmalzing,
T. Martin,
B. Lioure,
S. Weiner,
A. Kreuter,
C. Deligny,
J. Durand,
P. Emery,
K. Machold,
F. Sarrot-Reynauld,
K. Warnatz,
D. Adoue,
J. Constans,
H. Tony,
N. Del Papa,
A. Fassas,
A. Himsel,
D. Launay,
A. Lo Monaco,
P. Philippe,
I. Quéré,
É. Rich,
R. Westhovens,
B. Griffiths,
R. Saccardi,
F. V. D. van den Hoogen,
W. Fibbe,
G. Socié,
A. Gratwohl,
A. Tyndall
|
9 |
2014 |
9
🦁
|
|
🐜
|
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
21 auth.
V. Furer,
C. Rondaan,
M. Heijstek,
N. Agmon-Levin,
S. van Assen,
M. Bijl,
F. Breedveld,
R. D'Amelio,
M. Dougados,
M. Kapetanovic,
...
J. V. van Laar,
A. de Thurah,
R. Landewé,
A. Moltó,
U. Müller-Ladner,
K. Schreiber,
Leo Smolar,
Jim Walker,
K. Warnatz,
N. Wulffraat,
O. Elkayam
|
9 |
2019 |
9
🐜
|
|
🐜
|
Mortality in systemic sclerosis: an international meta-analysis of individual patient data.
15 auth.
J. Ioannidis,
P. Vlachoyiannopoulos,
A. Haidich,
T. Medsger,
M. Lucas,
C. Michet,
M. Kuwana,
H. Yasuoka,
F. V. D. van den Hoogen,
L. T. te Boome,
...
J. V. van Laar,
N. Verbeet,
M. Matucci-Cerinic,
A. Georgountzos,
H. Moutsopoulos
|
8 |
2005 |
8
🐜
|
|
🐜
|
Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells.
8 auth.
M. E. Morgan,
R. Flierman,
L. V. van Duivenvoorde,
Hendrik J. Witteveen,
W. van Ewijk,
J. V. van Laar,
...
R. de Vries,
R. Toes
|
8 |
2005 |
8
🐜
|
|
🐜
|
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
7 auth.
S. Jordan,
J. Distler,
B. Maurer,
D. Huscher,
J. V. van Laar,
Y. Allanore,
...
O. Distler
|
8 |
2014 |
8
🐜
|
|
🐜
|
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
16 auth.
D. Khanna,
Celia J. F. Lin,
D. Furst,
J. Goldin,
G. Kim,
M. Kuwana,
Y. Allanore,
M. Matucci-Cerinic,
O. Distler,
Y. Shima,
...
J. V. van Laar,
H. Spotswood,
Bridget Wagner,
J. Siegel,
A. Jahreis,
C. Denton
|
8 |
2020 |
8
🐜
|
|
🐢
|
The clinical utility of bone marker measurements in osteoporosis
G. Wheater,
M. Elshahaly,
S. Tuck,
H. Datta,
J. V. van Laar
|
8 |
2013 |
8
🐢
|
|
🐜
|
Involvement of functional autoantibodies against vascular receptors in systemic sclerosis
17 auth.
G. Riemekasten,
A. Philippe,
M. Näther,
T. Slowinski,
D. Müller,
H. Heidecke,
M. Matucci-Cerinic,
L. Czirják,
I. Lukitsch,
M. Becker,
...
A. Kill,
J. V. van Laar,
R. Catar,
F. Luft,
G. Burmester,
B. Hegner,
D. Dragun
|
8 |
2010 |
8
🐜
|
|
🐢
|
EULAR definition of difficult-to-treat rheumatoid arthritis
31 auth.
G. Nagy,
N. Roodenrijs,
P. Welsing,
M. Kedves,
A. Hamar,
M. C. van der Goes,
A. Kent,
M. Bakkers,
E. Blaas,
L. Šenolt,
Z. Szekanecz,
E. Choy,
M. Dougados,
J. Jacobs,
R. Geenen,
...
H. Bijlsma,
A. Zink,
D. Aletaha,
L. Schoneveld,
P. V. van Riel,
L. Gutermann,
Yeliz Prior,
E. Nikiphorou,
G. Ferraccioli,
G. Schett,
K. Hyrich,
U. Mueller-Ladner,
M. Buch,
I. McInnes,
D. M. van der Heijde,
J. V. van Laar
|
8 |
2020 |
8
🐢
|
|
🐜
|
Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis.
29 auth.
V. Smith,
A. Herrick,
F. Ingegnoli,
N. Damjanov,
Angelis,
C. Denton,
O. Distler,
Karinna Espejo,
I. Foeldvari,
T. Frech,
Boris Garro,
M. Gutierrez,
G. Gyger,
E. Hachulla,
R. Hesselstrand,
...
A. Iagnocco,
C. Kayser,
K. Melsens,
U. Müller-Ladner,
C. Pizzorni,
M. Radić,
V. Riccieri,
Marcus H Snow,
W. Stevens,
A. Sulli,
J. V. van Laar,
M. Vonk,
A. Vanhaecke,
M. Cutolo
|
8 |
2020 |
8
🐜
|
|
🐜
|
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
20 auth.
D. Khanna,
C. Denton,
Celia J. F. Lin,
J. V. van Laar,
T. Frech,
Marina E Anderson,
M. Baron,
L. Chung,
G. Fierlbeck,
S. Lakshminarayanan,
...
Y. Allanore,
J. Pope,
G. Riemekasten,
V. Steen,
U. Müller-Ladner,
H. Spotswood,
L. Burke,
J. Siegel,
A. Jahreis,
D. Furst
|
7 |
2017 |
7
🐜
|
